Onconetix, Inc. Interest Expense Nonoperating
Onconetix, Inc. (ONCO) reported Interest Expense Nonoperating of $4.39 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- Onconetix, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $4.39K, a 98.03% decline year-over-year.
- Onconetix, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $2.24K, a 99.00% decline year-over-year.
- Onconetix, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $4.25K, a 98.29% decline year-over-year.
- Onconetix, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $300.07K, a 29.53% increase year-over-year.
- Onconetix, Inc. interest expense nonoperating for fiscal 2025 was $751.00K, a 14.02% decline from fiscal 2024.
- Onconetix, Inc. interest expense nonoperating for fiscal 2024 was $873.43K, a 30.05% increase from fiscal 2023.
- Onconetix, Inc. interest expense nonoperating for fiscal 2023 was $671.63K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.39K 10-Q · filed 2026-08-13 | $6.63K 10-Q · filed 2026-08-13 | $10.88K derived: sum of 3 quarters · filed 2026-08-13 | $310.95K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.24K 10-Q · filed 2026-05-13 | $6.49K derived: sum of 2 quarters · filed 2026-05-13 | $306.56K derived: sum of 3 quarters · filed 2026-05-13 | $529.66K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $4.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $304.32K derived: sum of 2 quarters · filed 2026-03-13 | $527.41K derived: sum of 3 quarters · filed 2026-08-13 | $751.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $300.07K 10-Q · filed 2025-11-13 | $523.17K derived: sum of 2 quarters · filed 2026-08-13 | $746.76K 10-Q · filed 2025-11-13 | $995.11K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $223.10K 10-Q · filed 2026-08-13 | $446.69K 10-Q · filed 2026-08-13 | $695.04K derived: sum of 3 quarters · filed 2026-08-13 | $926.69K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $223.59K 10-Q · filed 2026-05-13 | $471.94K derived: sum of 2 quarters · filed 2026-05-13 | $703.60K derived: sum of 3 quarters · filed 2026-05-13 | $908.74K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $248.35K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $480.00K derived: sum of 2 quarters · filed 2026-03-13 | $685.15K derived: sum of 3 quarters · filed 2026-03-13 | $873.43K 10-K · filed 2026-03-13 |
| 2024-09-30 | $231.66K 10-Q · filed 2025-11-13 | $436.80K derived: sum of 2 quarters · filed 2025-11-13 | $625.08K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $205.15K 10-Q · filed 2025-08-14 | $393.43K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $187.99K 10-Q · filed 2025-06-12 | |||
| 2023-12-31 | $671.63K 10-K · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |